• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

MBX files for IPO, seeking cash to take challenger to Ascendis' Yorvipath into phase 3

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 26, 2024 at 10:22: AM
via MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3 development.

article source
 

<



Similar threads

cafead
MBX aims for $136M IPO to take potential rival to Ascendis&#039; Yorvipath into phase 3
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Respiratory disorder biotech Upstream Bio files for a $100 million IPO
Replies
0
Views
2
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BioAge files for IPO, plans pair of midstage obesity trials
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
23andMe CEO Anne Wojcicki files proposal to take company private as stock craters
Replies
0
Views
34
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote